| Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma SE Yoon, H Cho, P Berning, J Cho, HY Kim, DH Yoon, N Schmit, SJ Kim, ... Annals of Hematology, 1-11, 2024 | | 2024 |
| Comparison of CAR T-cell vs. bispecific antibody as third-or later-line large B-cell lymphoma therapy: A Meta-analysis J Kim, J Cho, MH Lee, SE Yoon, WS Kim, SJ Kim Blood, 2024 | | 2024 |
| Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies SJ Kim, SE Yoon, WS Kim Annals of laboratory medicine 44 (3), 210-221, 2024 | 3 | 2024 |
| Primary nodal Epstein-Barr virus-positive T-cell/NK-cell lymphoma: Real-world experience DH Choi, SE Yoon, J Cho, SJ Kim, WS Kim Acta Haematologica, 2024 | | 2024 |
| Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma SE Yoon, SH Shin, DK Nam, J Cho, WS Kim, SJ Kim Cancer Research and Treatment, 2024 | | 2024 |
| Tumor-infiltrating T lymphocytes evaluated using digital image analysis predict the prognosis of patients with diffuse large B-cell lymphoma Y Cho, J Lee, B Han, SE Yoon, SJ Kim, WS Kim, J Cho Journal of Pathology and Translational Medicine 58 (1), 12, 2024 | | 2024 |
| Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma YP Lee, SE Yoon, J Cho, YH Ko, D Oh, YC Ahn, WS Kim, SJ Kim Cancer Management and Research, 463-474, 2023 | | 2023 |
| A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma YP Lee, YJ Jung, J Cho, YH Ko, WS Kim, SJ Kim, SE Yoon Blood Research 58 (4), 208, 2023 | | 2023 |
| A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study SJ Kim, YR Do, HS Lee, WS Lee, JH Kong, JY Kwak, HS Eom, JH Moon, ... Blood Research 58 (4), 194, 2023 | | 2023 |
| Optimizing circulating tumor DNA limits of detection for DLBCL during first line therapy J Goldstein, WS Kim, SE Yoon, SJ Kim, M Roschewski, J Westin, ... Blood 142, 187, 2023 | 1 | 2023 |
| Real-World Data of Outcome of Patients with Newly Diagnosed Bronchial-Associated Lymphoid Tissue Lymphoma: A Multi-Center Retrospective Analysis with Long-Term Survivors K Kwak, Y Park, BS Kim, SE Yoon, WS Kim, KH Yoo, KW Kang, SJ Kim Blood 142, 6143, 2023 | | 2023 |
| Phase II study of Lenalidomide Maintenance after salvage therapy for relapsed or refractory peripheral T-Cell lymphomas SJ Kim, MW Lee, SN Lim, KW Kang, SE Yoon, YJ Lee, HJ Kang, HS Lee, ... Blood 142, 3073, 2023 | 1 | 2023 |
| Diverse Microbiome Characteristics in Treatment Naïve Extranodal NK/T-Cell Lymphoma Patients SE Yoon, W Kang, J Cho, J Hyeon, SJ Kim, WS Kim Blood 142, 5728, 2023 | | 2023 |
| Isatuximab and Cemiplimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Multi-Center, Open-Labeled Phase II Study (CISL2102/ICING study) SJ Kim, SE Yoon, DH Yang, SY Oh, YS Choi, SH Jeong, MK Kim, SN Lim, ... Blood 142, 301, 2023 | | 2023 |
| Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study BJ Sworder, SE Yoon, SJ Kim, A Schultz, G Hogan, S Close, JJ Chabon, ... Blood 142, 69, 2023 | | 2023 |
| Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma LJ Nastoupil, G Hess, MA Pavlovsky, I Danielewicz, J Freeman, ... Blood Advances 7 (22), 7141-7150, 2023 | 5 | 2023 |
| The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma SE Yoon, S Park, J Cho, KJ Ryu, B Yandava, S Lee, SJ Kim, WS Kim Frontiers in Oncology 13, 1194315, 2023 | 2 | 2023 |
| Differences in mutational signature of diffuse large B‐cell lymphomas according to the primary organ HH Koh, SE Yoon, SJ Kim, WS Kim, J Cho Cancer Medicine 12 (19), 19732-19743, 2023 | 1 | 2023 |
| Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation SJ Kim, JC Jo, DH Yoon, DH Yang, SE Yoon, GW Lee, JH Kong, Y Park, ... Frontiers in Oncology 13, 1230629, 2023 | 1 | 2023 |
| Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study S Park, JH Kim, S Kim, J Kang, S Moon, SJ Kim, JY Shin Blood Cancer Journal 13 (1), 123, 2023 | | 2023 |
Won Seog kimSamsung Medical CenterVerified email at skku.edu
